SCHEMBL2652367

SCHEMBL2652367

CCNC(=O)COC(=O)c1ccc2c(c1)ncn2-c1cccc(N2CCN(CCOC)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.47
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
HPGD P15428 8/20 0.44
MAPK1 P28482 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
RAB9A P51151 1/20 0.40
TP53 P04637 2/20 0.40
PRKAB2 O43741 1/20 0.40
ABL1 P00519 1/20 0.40
CSF1R P07333 1/20 0.40
LYN P07948 1/20 0.40
TGFBR1 P36897 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653616 0.93 KMT2A (0.50) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL2651654 0.92 FGFR1 (0.48) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL4704314 0.88 FGFR1 (0.51) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL2652930 0.88 FGFR1 (0.50) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL2652876 0.86 KMT2A (0.49) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL2652366 0.86 FGFR1 (0.47) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL4702087 0.85 FGFR1 (0.48) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL2653245 0.85 KMT2A (0.51) FGFR1KMT2AMEN1HPGDMAPK1
SCHEMBL2654312 0.85 FGFR1 (0.52) FGFR1KMT2AMEN1HPGDTP53
SCHEMBL2652293 0.85 FGFR1 (0.47) FGFR1KMT2AMEN1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP claimed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US claimed
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP disclosed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US disclosed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP disclosed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA2, GABRA1, GABRA5 FGFR1 2849/4885KMT2A 2056/4885MEN1 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.